BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 36045675)

  • 21. Are tumours angiogenesis-dependent?
    Verheul HM; Voest EE; Schlingemann RO
    J Pathol; 2004 Jan; 202(1):5-13. PubMed ID: 14694516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Broad targeting of angiogenesis for cancer prevention and therapy.
    Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
    Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.
    Weiss A; van Beijnum JR; Bonvin D; Jichlinski P; Dyson PJ; Griffioen AW; Nowak-Sliwinska P
    J Cell Mol Med; 2014 Mar; 18(3):480-91. PubMed ID: 24450440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
    De Bock K; Cauwenberghs S; Carmeliet P
    Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
    Jászai J; Schmidt MHH
    Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity.
    Tzeng HT; Huang YJ
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncometabolites lactate and succinate drive pro-angiogenic macrophage response in tumors.
    Kes MMG; Van den Bossche J; Griffioen AW; Huijbers EJM
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188427. PubMed ID: 32961257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour vessel remodelling: new opportunities in cancer treatment.
    Ganss R
    Vasc Biol; 2020; 2(1):R35-R43. PubMed ID: 32923973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucocorticoid-mediated effects on angiogenesis in solid tumors.
    Martens B; Drebert Z
    J Steroid Biochem Mol Biol; 2019 Apr; 188():147-155. PubMed ID: 30654109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vessel co-option and resistance to anti-angiogenic therapy.
    Kuczynski EA; Reynolds AR
    Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extracellular vesicle-mediated regulation of tumor angiogenesis- implications for anti-angiogenesis therapy.
    Zhang S; Yang J; Shen L
    J Cell Mol Med; 2021 Mar; 25(6):2776-2785. PubMed ID: 33586248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.
    Choi SH; Yoo SS; Lee SY; Park JY
    Arch Pharm Res; 2022 Apr; 45(4):263-279. PubMed ID: 35449345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies.
    Abou Khouzam R; Brodaczewska K; Filipiak A; Zeinelabdin NA; Buart S; Szczylik C; Kieda C; Chouaib S
    Front Immunol; 2020; 11():613114. PubMed ID: 33552076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
    Yetkin-Arik B; Kastelein AW; Klaassen I; Jansen CHJR; Latul YP; Vittori M; Biri A; Kahraman K; Griffioen AW; Amant F; Lok CAR; Schlingemann RO; van Noorden CJF
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188446. PubMed ID: 33058997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy.
    Kanthou C; Tozer G
    Br J Radiol; 2019 Jan; 92(1093):20180405. PubMed ID: 30160184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy.
    Schaaf MB; Garg AD; Agostinis P
    Cell Death Dis; 2018 Jan; 9(2):115. PubMed ID: 29371595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases.
    Carmeliet P; Jain RK
    Nat Rev Drug Discov; 2011 Jun; 10(6):417-27. PubMed ID: 21629292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic options to target angiogenesis in human malignancies.
    Herbst RS
    Expert Opin Emerg Drugs; 2006 Nov; 11(4):635-50. PubMed ID: 17064223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment.
    Schito L
    Am J Physiol Regul Integr Comp Physiol; 2018 Dec; 315(6):R1072-R1084. PubMed ID: 30183339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.